公开(公告)号：US10822325B2

公开(公告)日：2020-11-03

申请号：US15735840

申请日：2016-06-10

Applicant: UNM RAINFOREST INNOVATIONS ,  ROSALIND FRANKLIN UNIVERSITY

Inventor： Tudor I. Oprea ,  Cristian George Bologa ,  Oleg Ursu ,  Jun-Yong Choe ,  Cristina Iancu

IPC: C07D317/66 ,  A61K31/36 ,  A61P3/10 ,  G16B35/00 ,  G16C20/60 ,  C07C317/36 ,  A23L33/125 ,  A61K45/06

Abstract: The present invention relates to compounds which have been discovered to be potent ligands (inhibitors) of human GLUT5 (glucose transporter type 5), a facilitative glucose transporter that transports fructose, and their use as ligands assays which can uncover additional ligands of GLUT5, having the potential for being used as drugs. In addition, the present invention is directed to compounds, chemical compositions and methods for treating disease states and conditions which are mediated through GLUT5, including such disease states and conditions as GLUT5 deficiency syndrome, diabetes (type I and II), cancer, metabolic diseases including metabolic syndrome and fatty liver disease, among others.

公开(公告)号：US20210041441A1

公开(公告)日：2021-02-11

申请号：US16978364

申请日：2019-03-08

Applicant: UNM Rainforest Innovations ,  The University of North Carolina at Chapel Hill

Inventor： Larry A. Sklar ,  Tudor I. Oprea ,  Anna Waller ,  Angela Wandinger-Ness ,  Mark K. Haynes ,  Sharon Campbell ,  Harold A. Ames

IPC: G01N33/574 ,  A61K31/407 ,  A61K31/155

Abstract: The present invention is directed to compounds, compositions and methods for modulating RAS family GTPases, in particular KRas, HRas and NRas GTPases. These GTPases are upregulated in cancer and in other tissue and represent appropriate targets for therapy. Methods for identifying the activity of compounds with respect to these and other GTPases in multiplex flow cytometry systems represents another aspect of this invention.

公开(公告)号：US20180170897A1

公开(公告)日：2018-06-21

申请号：US15735840

申请日：2016-06-10

Applicant: STC.UNM ,  ROSALIND FRANKLIN UNIVERSITY

Inventor： Tudor I. Oprea ,  Cristian George Bologa ,  Oleg Ursu ,  Jun-Yong Choe ,  Cristina Iancu

IPC: C07D317/66 ,  A61K31/36 ,  A61K45/06 ,  C40B30/02 ,  A23L33/125

Abstract: The present invention relates to compounds which have been discovered to be potent ligands (inhibitors) of human GLUT5 (glucose transporter type 5), a facilitative glucose transporter that transports fructose, and their use as ligands assays which can uncover additional ligands of GLUT5, having the potential for being used as drugs. In addition, the present invention is directed to compounds, chemical compositions and methods for treating disease states and conditions which are mediated through GLUT5, including such disease states and conditions as GLUT5 deficiency syndrome, diabetes (type I and II), cancer, metabolic diseases including metabolic syndrome and fatty liver disease, among others.